Comment on: Target-based discovery of a broad-spectrum flukicide
Timir Tripathi · 2024
Read Comment on: Target-based discovery of a broad-spectrum flukicide by Timir Tripathi (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11602114.txt.
Description
Timir Tripathi, writing alone in 2024, comments on a new drug candidate against parasitic flukes. The standard fluke drug, triclabendazole, kills liver flukes by wrecking their internal scaffolding and energy use, but resistance is spreading. The other main drug, praziquantel, cannot touch these flukes at all because of one amino acid change in its target channel.
The commented study found a compound, BZQ, that switches that same channel on across many fluke species, including resistant liver flukes. In lab tests it paralyzed worms and damaged their skin much like praziquantel does in other species. In mice it cut worm burden about as well as the standard drug. Tripathi weighs what a broad-spectrum activator could mean for treatment.
Catalog record
| CREATOR | Timir Tripathi |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 11 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |